Frog Prince transposon-based RNAi vectors mediate efficient gene knockdown in human cells by Kaufman, Christopher D et al.
 
© Kaufman et al | Journal of RNAi and Gene Silencing | October 2005 | Vol 1, No 2 | 97-104 | OPEN ACCESS 
97 
 




Frog Prince transposon-based RNAi vectors mediate efficient gene knockdown 





1 and Zoltán Ivics
1* 
 
1Max  Delbrück  Center  for  Molecular  Medicine,  13092  Berlin,  Germany. 
2Institute  of  Biochemistry,  Biological 
Research Center of the Hungarian Academy of Sciences, 6726 Szeged, Hungary  
 
*Correspondence to: Zoltán Ivics, Email: zivics@mdc-berlin.de, Tel: +49 30 9406 2546, Fax: +49 30 9406 2547 
 
Journal of RNAi and Gene Silencing (2005), 1(2), 97-104 
© Copyright Christopher D Kaufman et al 
 
(Received 07 June 2005; Revised 04 July 2005; Accepted 06 July 2005; Available online 02 September 2005; Published 





We have developed a stable RNA interference (RNAi) delivery system that is based on the Frog Prince 
transposable  element.  This plasmid-based  vector  system  combines the gene  silencing  capabilities  of H1 
polymerase III promoter-driven short hairpin RNAs (shRNA) with the advantages of stable and efficient 
genomic integration of the shRNA cassette mediated by transposition. We show that the Frog Prince-based 
shRNA  expressing  system  can  efficiently  knock  down  the  expression  of  both  exogenous  as  well  as 
endogenous genes in human cells. Furthermore, we use the Frog Prince-based system to study the effect of 
knockdown of the DNA repair factor Ku70 on transposition of the Sleeping Beauty transposon. Transposon-
mediated genomic integration ensures that the shRNA expression  cassette and a selectable marker gene 
within the transposon remain intact and physically linked. We demonstrate that a major advantage of our 
vector  system  over  plasmid-based  shRNA  delivery  is  both  its  enhanced  frequency  of  intact  genomic 
integration  as  well  as  higher  target  suppression  in  transgenic  human  cells.  Due  to  its  simplicity  and 
effectiveness, transposon-based RNAi is an emerging tool to facilitate analysis of gene function through the 
establishment of stable loss-of-function cell lines. 
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The  recent  discovery  and  development  of  RNA 
interference  (RNAi)  to  knock  down  the  expression  of  a 
gene-of-interest has brought a widely applicable tool into 
the toolbox  of the molecular or developmental biologist. 
RNAi is a mechanism of post-transcriptional gene silencing 
mediated by double-stranded RNA (dsRNA) (reviewed in 
Fire, 1999). While introduction of long dsRNA works well 
in such organisms as C. elegans and Drosophila, it induces 
a strong cytotoxic effect in mammalian somatic cells (Gil 
and  Esteban,  2000).  Synthetic,  21-23-nucleotide  short 
interfering RNAs (siRNAs) were shown to circumvent this 
response  (Caplen  et  al,  2001;  Elbashir  et  al,  2001). 
However, despite their efficient and specific suppression of 
gene  expression,  siRNAs  are  costly  to  manufacture,  the 
silencing  effect  is  short-lived,  and  generation  of  stable 
knock-down  cell  lines  (or  organisms)  is  not  possible.  A 
refinement  of  this  technique  demonstrated  that  vector-
based  siRNAs  allowed  efficient  gene  silencing  in 
transgenic  cell  derivatives  due  to  stable  chromosomal 
integration. These vectors express siRNAs through either 
convergent or divergent transcription (Miyagishi and Taira, 
2002; Tran et al, 2003), or by expression from an RNA 
polymerase III (pol III) promoter, such as U6 or H1, of a 
hairpin-containing  inverted  repeat,  called  short-hairpin 
RNA  (shRNA)  (Brummelkamp  et  al,  2002;  Paul  et  al, 
2002; Yu et al, 2002). 
 
Initially, plasmid DNA was used as the vector, but this is 
inefficient  in  chromosomal  integration.  Stable  cell  lines 
containing and expressing shRNAs can be generated  by 
cotransfection  of  a  selectable  marker  or  by  placing  the 
selectable  marker  on  the  shRNA  expression  plasmid  
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(Brummelkamp et al, 2002). However, expression of the 
selectable  marker  does  not  guarantee  that  the  shRNA 
expression cassette is integrated and that it is expressed at 
a level high enough to elicit the desired silencing effect in 
either  of  these  cases.  This  is  because  chromosomal 
integration of plasmid constructs is probably preceded by 
random  breakage  in  the  plasmid,  which  could  prevent 
linkage of the marker and the shRNA expression cassette 
(Bishop,  1996).  Viral  vectors,  such  as  retroviruses  and 
lentiviruses,  were  developed  to  alleviate  these  problems 
(Abbas-Terki  et  al,  2002;  Devroe  and  Silver,  2002). 
However,  viral  vectors  impose  problems,  such  as  a 
requirement for specialized laboratories, and complicated 
construction  and  preparation.  Clearly,  RNAi  technology 
would benefit from the development of simple, plasmid-
based  vector  systems  that  allow  efficient  chromosomal 
integration  and  stable  expression  of  shRNA  expression 
cassettes both in tissue culture and in vivo. 
 
Transposable  elements  are  mobile,  discrete  segments  of 
DNA that can catalyze their excision from one locus and 
reintegrate into another. These so-called "jumping genes", 
often  considered  junk  or  parasitic  DNA,  have  been 
harnessed and developed into useful genetic tools (Cooley 
et  al,  1988;  Plasterk,  1996).  In  particular,  the  Sleeping 
Beauty (SB) element, a reconstructed, active member of 
the Tc1/mariner superfamily (Ivics et al, 1997), has been 
developed  as  an  efficient  vector  for  gene  transfer  and 
insertional mutagenesis in vertebrates (Clark et al, 2004; 
Davidson et al, 2003; Dupuy et al, 2001; Grabher et al, 
2003; Horie et al, 2001; Luo et al, 1998). The application 
of SB as a vector for human gene therapy is also being 
actively  explored  (reviewed  in  Izsvák  and  Ivics,  2004), 
given  its  simple  construction  and  maintenance,  efficient 
chromosomal integration, long-term transgene expression 
and relative safety when compared to viral vectors. Two 
recent reports have shown the utility of the SB system as 
an  shRNA  vector.  Heggestad  et  al  (2004)  demonstrated 
stable  knockdown  of  both  GFP  and  lamin  A,  whereas 
Chen and colleagues reported long-lasting knockdown of 
the human huntingtin transcript in human cells (Chen et al, 
2005).  The  availability  of  multiple,  transposon-based 
vector systems broadens the utility of these elements as 
genetic tools. Thus, another transposon of the Tc1/mariner 
superfamily, named Frog Prince (FP), was reconstructed 
from inactive elements found in the genome of the frog 
species Rana pipiens (Miskey et al, 2003). FP transposes 
through  a  "cut-and-paste"  mechanism  catalyzed  by  the 
transposase  encoded  between  the  two  terminal  inverted 
repeats (IRs). The transposase can  be supplied in trans, 
allowing replacement of the transposase coding sequence 
with a cargo gene of choice located between the required 
IRs (Figure 1). 
 
In  this  work,  we  assessed  the  utility  of  FP-based 
transposon vectors for efficient delivery and expression of 
shRNAs in cultured mammalian cells. We show that FP-
based shRNA vectors can efficiently transpose in human 
cells.  We  further  demonstrate  efficient  knockdown  of 
expression  of  the  exogenous  marker  gene  EGFP,  and 
substantial  inhibition  of  the  function  of  the  endogenous 
double-strand break repair factor Ku70. The data establish 
the Frog Prince transposon as a useful tool for the easy 
and efficient generation of stable knockdown cell lines for 
a variety of genetic analyses. 
 
MATERIALS AND METHODS 
 
Plasmids 
The pEGFP-C1 plasmid was obtained from Clontech (Palo 
Alto, CA, USA). The pSUPER plasmid was obtained from 
R.  Agami  (Brummelkamp  et  al,  2002).  The  neomycin 
phosphotransferase (neo) marked FP transposon, pFP/Neo, 
as previously described (Miskey et al, 2003), was digested 
with HindIII, Klenow-filled, and religated to remove the 
HindIII site on the vector backbone. The human H1 RNA 
polymerase  III  driven  shRNA  expression  cassette  was 
isolated from pSUPER  with  XbaI  and HincII  restriction 
digestion,  Klenow-filled  and  ligated  into  pFP/Neo 
previously digested with BglII and Klenow-filled. The H1 
shRNA  cassette  was  subcloned  between  the 
polyadenylation  signal  of  the neo  cassette  and  the right 
IR/DR  of  the  FP  transposon.  Double-stranded  oligos 
encoding the gene-specific hairpin RNA were subcloned 
into the BglII/HindIII site of the H1 shRNA cassette. Due 
to  the  immediate  proximity  of  these  two  restriction 
enzyme  sites,  difficulties  were  encountered  in  efficient 
digestion  with  both  enzymes.  Thus,  a  0.3  kb  spacer 
fragment of non-specific DNA was cloned into the HindIII 
site to alleviate this problem. The zeocin resistance gene 
(Zeo)  marked  SB  transposon,  pT/Zeo,  was  constructed 




Figure 1. Schematic of Frog Prince-based shRNA vectors. (A) The parental FP transposon contains the neomycin resistance gene 
(NEO) driven by the SV40 promoter (SV40) and followed by the SV40 polyadenlyation signal (SV40-pA) between the left and right 
flanking terminal inverted repeats (IR). (B) The H1 promoter expression cassette from pSUPER was subcloned between the 
polyadenylation signal and the right IR to generate pFP/Neo-H1. 
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The following oligos were synthesized (Biotez, Berlin, 
Germany), using parameters established in (Reynolds et 
al,  2004;  Ui-Tei  et  al,  2004):  EGFP4(482)F 
gatccccGCATCAAGGTGAACTTCAAttcaagagaTTGA
AGTTCACCTTGATGCtttttggaaa,  EGFP4(482)R 
agcttttccaaaaaGCATCAAGGTGAACTTCAAtctcttgaaT
TGAAGTTCACCTTGATGCggg,  Ku70  (1148)F 
gatccccGGATCATGCTGTTCACCAAttcaagagaTTGG
TGAACAGCATGATCCtttttggaaa  and  Ku70(1148)R 
agcttttccaaaaaGGATCATGCTGTTCACCAAtctcttgaaT
TGGTGAACAGCATGATCCggg.  The  numbers  in 
parentheses refer to the start nucleotide  of the  5'  sense-
strand, relative to the start codon of the target transcript. 
Sequences in lower case are flanking and loop sequences, 
as  recommended  (Brummelkamp  et  al,  2002).  Flanking 
sequences give compatible overhangs for BglII on the 5'- 
and HindIII on the 3'-end of the oligo. Respective forward 
and  reverse  oligos  were  annealed,  phosphorylated,  and 
ligated  into  pFP-H1  or  pFP-H1/bi,  previously  digested 
with first BglII, then HindIII, and then dephosphorylated. 
Subclones  were  screened  with  EcoRI/HindIII  restriction 
digestion and confirmed by sequencing. 
 
Cell culture and transfection 
Cells were cultured in DMEM (Gibco, Karlsruhe, Germany) 
supplemented  with  10%  (v/v)  fetal  calf  serum  (PAA, 
Pasching,  Austria)  at  37°C  and  5%  (v/v)  CO2. 
Approximately 5 x 10
5 HeLa cells were plated out one day 
prior  to  transfection  into  6-well  plates.  Purified  plasmid 
DNA  (Qiagen,  Hilden,  Germany)  was  transfected  with 
Fugene6  (Roche,  Mannheim,  Germany).  Two  days  after 
transfection, cells were seeded into 10 cm dishes in DMEM 
plus  1.4  mg/ml  G418  (Gibco,  Karlsruhe,  Germany)  and 
selected for two weeks. G418-resistant colonies were picked 
and expanded for generation of stable clones. 
 
The  HeLa  EGFP  clonal  line  H38-3  was  made  by 
cotransfection  of  pT/EGFP  (Z.  Ivics,  unpublished  data), 
pCMV-SB transposase expressing helper plasmid (Ivics et 
al, 1997), and pHygro (Clontech, Palo Alto, CA, USA). 
Hygromycin-resistant  (Invitrogen,  Karlsruhe,  Germany; 
150  µg/ml)  colonies  were  individually  picked  after  two 
weeks of selection and assayed for EGFP expression by 
fluorescent  microscopy  and  flow  cytometry  (FACS) 
analysis  on  a  FACSCalibur  (Becton  Dickinson, 
Heidelberg,  Germany).  An  EGFP-expressing  transgenic 
clone  was  subcloned  by  limiting  dilution  to  obtain  the 
clonal line H38-3. 
 
EGFP knockdown analysis 
H38-3 cells were transfected as described above with 800 
ng of pFP/Neo-H1 with or without an shRNA oligo, plus 
the FP transposase helper plasmid pFV-FP (Miskey et al, 
2003). As control, 800 ng of the pSUPER plasmid with or 
without an shRNA oligo was cotransfected with pFP/Neo 
to allow G418 selection. The transfected cells were seeded 
to a 10 cm dish with 1.4 mg/ml G418 and selected for two 
weeks.  G418-resistant  colonies  were  pooled,  and  EGFP 
expression  was  assayed  by  fluorescent  microscopy  and 
FACS  analysis.  The  mean  EGFP  fluorescence  was 
calculated by CELLQuest V3.1 (Becton Dickinson). For 
analysis in 96-well format, transfected H38-3 cells were 
diluted into DMEM containing 1.4 mg/ml G418 and plated 
with a multichannel pipette into black, clear bottom 96-
well  plates  (Corning,  NY,  USA)  two  days  after 
transfection.  After  two  weeks  of  selection,  EGFP 
expression levels were measured with a platereader (Bio-
Tek  Synergy  HT,  Bad  Friedrichshall,  Germany)  and 
analyzed  with  KC4  V3.3  software.  Colonies  were  then 
fixed, stained, and counted. EGFP values per colony were 
graphically  displayed  using  Treeview  1.60 
(http://rana.lbl.gov/EisenSoftware.htm). 
 
Transient  Ku70  knockdown  was  analyzed  using  western 
hybridization  as  previously  described  (Izsvák  et  al,  2004). 
Stable Ku70 knockdown cell lines were functionally assayed 
for reduced Ku70 activity by a transposition assay (Ivics et al, 
1997). The SB transposon pT/Zeo was cotransfected with the 
pCMV-SB transposase helper plasmid into each clonal line. 
Cells  were  selected  with 100  µg/ml  of zeocin (Invitrogen, 
Karlsruhe, Germany) for two weeks before resistant colonies 




Frog Prince transposon-based shRNA vectors 
Transpositional activity of FP is similar to, if not higher 
than,  SB  in  diverse  vertebrate  cell  lines  (Miskey  et  al, 
2003). Thus, it is an ideal candidate for a transposon-based 
shRNA  vector.  The  H1  pol  III  promoter  expression 
cassette from pSUPER (Brummelkamp et al, 2002) was 
subcloned into the FP transposon to drive expression of 
shRNAs. The H1 expression cassette was subcloned into 
the  3'  end  of  the  FP  transposon,  between  the 
polyadenylation  signal  of  the  neomycin-resistance  (neo) 
expression cassette and the right terminal inverted repeat, 
and  the resulting  construct  was  denoted  as  pFP/Neo-H1 
(Figure 1B). The H1 cassette insertion was recovered in 
both  orientations  relative  to  the  direction  of  neo  gene 
transcription. Both transposon constructs were tested for 
transpositional activity with a standard transposition assay 
(Ivics  et  al,  1997)  in  human  HeLa  cells.  Both  versions 
transposed equally well, and almost as well as the parental 
transposon pFP/Neo (data not shown). 
 
Stable EGFP knockdown 
EGFP  was  chosen  as  the  initial  target  for  proof-of-
principle  tests.  Four  anti-EGFP  shRNA  oligonucleotides 
were designed using web-based parameters, and subcloned 
into both pSUPER and pFP/Neo-H1 for transient analysis. 
One of these (hereafter referred to as EGFP4) resulted in 
over  90%  reduction  in  mean  EGFP  fluorescence  in 
transient  transfection  assays  using  both  pSUPER-based 
and transposon-based vectors with either orientation of the 
H1 shRNA expression cassette (data not shown). Thus, the 
pFP/Neo-H1  transposon  vector  (Figure  1B)  and  the 
EGFP4 oligo were chosen to test long-term knockdown of 
EGFP expression mediated by the Frog Prince transposon. 
The EGFP4 shRNA oligo was subcloned into pFP/Neo-H1 
to generate pFP/Neo-H1/EGFP4. EGFP knockdown was 
examined in a stably transgenic, HeLa-derived, EGFP-
expressing  clonal  cell  line  (H38-3).  To  generate 
transposition-mediated  transgenic  cells,  H38-3  cells 
were  cotransfected  with  the  transposon-based  shRNA 
vector and  the  FP transposase expression plasmid pFV-
FP  (Miskey et al, 2003).  In  “no-transposition”  control   




Figure 2. Stable FP-shRNA-mediated knockdown of EGFP in pooled HeLa colonies. The EGFP clonal HeLa cell line H38-3 was 
cotransfected with the indicated shRNA expressing plasmid plus either a transposase source or a neomycin expression plasmid. 
Transfected cells were selected with G418 for two weeks, and resistant colonies were harvested and pooled together. EGFP 
expression was analyzed by FACS. The mean EGFP expression of the H38-3 parental line was arbitrarily set to 100%. The respective 
overlaid FACS profiles are shown in the inset. 
 
 
experiments, pS/EGFP4 was cotransfected with pFP/Neo 
as a selectable marker to allow colony selection. Another, 
“no-shRNA”  control  line  was  made  by  cotransfecting 
H38-3 cells with pFP/Neo-H1 plus pFV-FP.  
 
Pooled  colonies  were  assayed  for  EGFP  fluorescence 
levels by FACS between 35 and 66 days post-transfection, 
and compared to the parental line H38-3. The mean EGFP 
fluorescence of each sample was compared to the mean 
EGFP  of  the  parental  line,  which  was  arbitrarily  set  to 
100% (Figure 2). Both pSUPER- and pFP-based shRNA 
resulted  in  about  85-90%  reduction  in  mean  EGFP 
fluorescence,  respectively,  relative  to  parental  levels 
(Figure  2). In comparison, transgenic cells  generated by 
the  pFP/Neo-H1  transposon  had  a  mean  EGFP 
fluorescence  approximately  equal  to  H38-3  (Figure  2). 
Thus, Frog Prince-based shRNA can efficiently mediate 
stable silencing of an exogenously introduced gene. 
 
FP-based shRNA vectors are more efficient at colony 
formation  and  EGFP  knockdown  than  non-
transposon-based plasmid vectors 
We showed that the FP-based shRNA system is capable of 
knocking  down  EGFP  expression  in  pooled  transgenic 
cells, but how does the efficiency of both transgenesis and 
knockdown  compare  to  non-transposon  systems?  To 
answer this  question, an assay was  established  to  allow 
direct  comparison  between  the  numbers  of  antibiotic-
resistant  colonies  generated  and  the  level  of  EGFP 
expression per colony. H38-3 HeLa cells were transfected 
with  either  pFP/Neo-H1-EGFP4  plus  pFV-FP 
(transposition-mediated  stable  transgenesis)  or  with 
pS/EGFP4  plus  pFP/Neo  as  a  selectable  marker  (“no-
transposition” control). The cells were plated to a 96-well 
plate such that pFP/Neo-H1-EGFP4-transfected cells gave 
at least one colony in almost every well. After two weeks 
under G418 selection, the level of EGFP expression per 
well was measured using a plate reader. The cells were 
then fixed, stained, and the colonies counted. The value of 
EGFP expression per colony was calculated and expressed 
in  a  graphical  format.  In  Figure  3,  each  rectangle 
represents a 96-well plate, with each pixel being one well. 
The pixels are color-coded according to the level of EGFP 
expression per colony - with black meaning no colonies, 
and increasingly lighter shades of green meaning higher 
EGFP expression per colony. pFP/Neo-H1-EGFP4 (Figure 
3B)  was  clearly  more  efficient  at  forming  antibiotic 
resistant colonies, as 95 of the 96 wells contained colonies, 
whereas  only  52  of  96  wells  contained  colonies  for 
pS/EGFP4 (Figure 3A). Furthermore, the average level of 
EGFP  expression  in  wells  with  colonies  was  overall 
reduced  in  pFP/Neo-H1-EGFP4  colonies  compared  to 
pS/EGFP4. We conclude that FP transposon-based shRNA 
vectors are more efficient at colony formation and EGFP 
knockdown than non-transposon, plasmid-based vectors. 
 
Frog  Prince-based  shRNA  can  efficiently  mediate 
silencing of an endogenous gene 
We  next  tested  the  ability  of  the  FP-shRNA  system  to 
silence an endogenous gene. The Ku70/80 complex is a 
component  of  the  nonhomologous  end  joining  (NHEJ) 
pathway  of  DNA  double  strand  break  (DSB)  repair 
(Durocher and Jackson, 2001). The Ku protein complex 
has  been  shown  to  be  required  for  efficient  SB 
transposition  (Izsvák  et  al,  2004;  Yant  and  Kay,  2003). 
This  was  studied  by  measuring  the  efficiency  of  SB 
transposition  in  cells  with  a  Ku-deficient  genetic 
background,  and  in  wild-type  cells  in  which  Ku80 was   





Figure 3. Comparison of efficiencies of colony formation and 
EGFP knockdown with pSUPER- versus pFP-based shRNA 
vectors. The EGFP clonal HeLa line H38-3 was cotransfected 
with (A) pSUPER/EGFP4 and pFP/Neo, or (B) pFP/Neo-
H1/EGFP4 and pFV-FP. Two days after transfection, the cells 
were diluted and plated into 96-well plates. After two weeks 
under G418 selection, EGFP expression was analyzed for 
resistant colonies in each well with a plate reader. Colonies were 
then fixed, stained and counted. The EGFP expression level per 
colony was calculated and graphically displayed using the 
Treeview program. Each square pixel represents a well and is 
color-coded. Black represents empty wells, while the shades of 
green reflect the level of EGFP expression per colony, with dark 
meaning a low level and bright meaning a high level. 
 
 
transiently  knocked  down  with  RNAi.  Thus,  a  colony-
forming transposition assay has been shown to serve as a 
simple  and  efficient  functional  test  of  Ku  knockdown 
(Izsvák et al, 2004). 
 
An shRNA oligo was designed against the human Ku70 
transcript and subcloned into the pSUPER and pFP/Neo-
H1  vectors.  The  resulting  shRNA-expressing  constructs 
were transiently transfected into HeLa cells, and the ability 
of  the  shRNA  to  knock  down  endogenous  Ku70 
expression was assayed using Western hybridization. As 
shown  in  Figure  4A,  the  anti-Ku70  shRNA  clearly 
diminished levels of Ku70 protein, whereas cellular levels 
of  actin  remained  unchanged.  Then,  HeLa  cells  were 
transfected with pSUPER (negative control), pS/Ku70 and 
pFP/Neo-H1-Ku70, and individual transgenic cell clones 
were  isolated  from  each  transfection.  pSUPER  and 
pS/Ku70 were cotransfected with pFP/Neo as a marker to 
allow colony selection. The pFP/Neo-H1-Ku70 construct 
was transfected both in the presence and absence of pFV-
FP to monitor FP transpositional efficiency. In the absence 
of transposase (in this experiment pCMV-Beta, encoding 
β-galactosidase,  replaced  the  transposase  expression 
plasmid,  Figure  4B),  transgene  integration  occurred 
randomly  rather  than  by  transposition,  and  served  as  a 
control. Similar to SB transposition, the shRNA-mediated 
knockdown  of Ku70 clearly  interfered with efficient FP 
transposition (data not shown). However, FP transposase-
mediated  transposition  of  pFP/Neo-H1-Ku70  was  still 
higher  than  random  plasmid  integration,  allowing  easy 
establishment of stable colonies. Individual colonies were 
picked for each construct and expanded under selection for 
up  to  three  months.  Since  the  SB  and  FP  transposases 
share only 50% amino acid identity, and they were shown 
not to cross-mobilize each other (Miskey et al, 2003), it 
was  possible  to  test  the  efficacy  of  the  Ku70  shRNA 
constructs using a SB transposition assay. 
 
Thus, to characterize the knockdown capacity of the stably 
integrated shRNA constructs, antibiotic-resistant colonies 
from each experiment were assayed for SB transposition. 
The level of SB transpositional efficiency is a measure of 
Ku70  activity,  such  that  diminished  SB  activity  reflects 
increased Ku70 knockdown. The transpositional efficiency 
of  SB in  pSUPER  stable  colonies  was  arbitrarily  set  to 
100%. Five categories were established to characterize the 
efficiency of the knockdown effect: 0, 10-25, 25-50, 50-
75,  and  75-100%  reduction  in  SB  transposition.  The 
results  in  Figure  4B  show  that  in  a  sample  size  of  24 
colonies,  over  60%  of  the  transposition-generated 
(pFP/Neo-H1-Ku70  plus  pFV-FP)  clones  had  a 
knockdown effect of 75-100%. However, this number was 
only  about  30%  for  pS/Ku70  clones  (Figure  4B). 
Furthermore,  over  90%  of  the  transposition-generated 
clones showed at least 50% knockdown of Ku70 activity 
whereas only 46% of pS/Ku70 clones were at this level 
(Figure  4B).  In  the  clones  generated  with  pFP/Neo-H1-
Ku70 in the absence of transposase (a situation similar to 
the  next  generation  of  pSUPER-based  plasmids  that 
contain  a  selectable  marker),  the  observed  knockdown 
effect was intermediate, with about 40% of the colonies in 
the 75-100% category (Figure 4B). Taken together, these 
results  show  that the  efficacy  of  the  transposition-based 
system  is  greater  than  the  plasmid-based  system  in 
reducing  the  function  of  an  endogenous  gene. 
Furthermore, these results confirm the importance of the 





We showed that the Frog Prince-based shRNA system is 
capable  of  knocking  down  both  exogenous  as  well  as 
endogenous  transcripts  in  human  cells.  In  addition,  it 
functions both transiently and in stable cell clones, either 
individually picked or pooled. Our results show that both 
the  number  and  the  knockdown  effect  of  shRNA-
expressing colonies are higher with the transposon- versus 
the plasmid-based approach. When the transposon vector 
system is used for establishing stable knockdown lines, the 
probability that an antibiotic-resistant clone is also a good 
knockdown  clone  was  higher  (Figures  3  and  4B).  One 
explanation  is  that  transposition-mediated  genomic 
integration  maintains  the  shRNA  cassette  and  the 
selectable marker physically linked within the transposable 
element.  This  can  enhance  the  stability  of  the  gene  





Figure 4. Efficiency of FP-shRNA-mediated knockdown of Ku70 in HeLa cells assayed by Western hybridization and Sleeping 
Beauty transposition. (A) Western hybridizations of nuclear protein extracts prepared from HeLa cells transiently transfected with the 
plasmid constructs shown above the lanes. Nuclear extracts from each transfection were blotted and hybridized with a Ku70 antibody 
(upper panel) or with an actin antibody (lower panel). (B) Efficiency of SB transposition in transgenic cell clones expressing shRNAs 
against Ku70. The indicated numbers of colonies (n) from each transfection were picked and expanded under selection. A 
transposition assay using a zeocin resistance gene-marked SB transposon and a SB transposase helper plasmid was performed in each 
clone. After two weeks under zeocin selection, resistant colonies were stained and counted. The efficiency of SB transposition in 
each picked clone was grouped into five categories: 0, 1-25, 25-50, 50-75 and 75-100% reduction, relative to the level of SB 
transposition in the pSUPER control clones. 
 
 
knockdown effect, compared to non-transposase-mediated 
integration,  where  the  cleavage  of  the  plasmid  DNA 
occurs  randomly  prior  to  chromosomal  integration 
(Bishop, 1996), which may lead to physical separation of 
the selectable maker and the shRNA expression cassette. 
Transposition-mediated  integration  provided  more 
efficient knockdown than random integration even when 
the  selectable  marker  was  provided  in  cis  (Figure  4B, 
compare pFP/Neo-H1-Ku70 in the presence and absence 
of  transposase),  showing  that  the  precise  cut-and-paste 
mechanism  of  transposition  is  superior  to  random 
integration  for  maintaining  linkage  of  the  shRNA 
expression cassette and the selectable marker. 
 
The  transposon-based  shRNA  system  also  has  several 
advantages over viral systems. Transposons, in contrast to 
viral  vectors,  are  quick,  simple  and  cost-effective  to 
produce, and are not infectious, thus do not pose potential 
safety risks to the investigator. Additionally, integration of 
transposons into the genome is random (Liu et al, 2005;  
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Vigdal  et  al,  2002;  Yant  et  al,  2005),  in  contrast  to 
retroviruses,  lentiviruses  (Mitchell  et  al,  2004)  and 
recombinant  adeno-associated  viruses  (Nakai  et  al, 
2005)  that  tend  to  prefer  to  integrate  into  expressed 
genes. This random integration of transposons represents 
a  reduced  chance  of  interrupting  a  gene  that  is  either 
essential  for  cell  survival  or  that  could  lead  to  non-
specific  gene  expression  effects.  In  comparison  to 
viruses and in contrast to plasmid vectors, transposons 
integrate through a precisely mediated mechanism that 
can  promote  stable  transgene  expression  over  a  long 
period  of  time.  Here  we  show  that  the  FP-shRNA 
mediated knockdown of EGFP in a transgenic line can 
persist  for  at  least  six  weeks  (Figure  2)  and  that 
functional  knockdown  of  Ku70  can  persist  for  up  to 
three  months  (Figure  4B).  Together  with  previous 
studies demonstrating Sleeping Beauty transposon-based 
stable knockdown of gene expression (Heggestad et al, 
2004;  Chen  et  al,  2005),  these  data  establish  the 
advantages of transposon-based shRNA vectors for both 
stable and long-term knockdown of a target transcript. 
The  availability  of  multiple  transposon-based  RNAi 
vectors  increases  the  utility  of  these  elements  for 
regulating  gene  expression  in  vertebrates.  We  have 
demonstrated  that  the  Frog  Prince  and  the  Sleeping 
Beauty transposon systems can be used in combination 
in certain applications. Specifically, the FP transposition 
process  was  used  to  deliver  the  shRNA  expression 
cassette from a plasmid DNA source into chromosomes, 
and  the  effect  of  the  shRNA-mediated  knockdown  of 
Ku70 was assayed using the SB transposon system. This 
allows the unique situation in which one transposon can 
be  used  as  a  tool  to  study  the  transpositional 
requirements (e.g., host factors) of the other. 
 
The  FP-shRNA  system  lends  itself  not  only  to 
generation of stable knockdown lines in cell culture, but 
also to generation of knockdown model organisms. The 
FP transposon system has shown activity in a wide host 
range of vertebrate cell types in culture (Miskey et al, 
2003),  as  well  as  in  zebrafish  embryos  (C.  Miskey, 
unpublished data). The related transposon, SB, has been 
extensively  used  for  genetic  engineering  of  vertebrate 
species such as fish, frogs and mice (reviewed in Ivics 
and  Izsvák,  2004;  Miskey  et  al,  2005).  With  the 
inclusion  of  either  an  inducible  promoter  or  a  tissue-
specific promoter (reviewed in Prawitt et al, 2004), the 
FP-shRNA  system  would  allow  spatial  and  temporal 
control over the silencing of developmentally important 
or  essential  genes,  as  well  as  generation  of  animal 
models of human disease through localized inhibition of 
specific targets.  
 
RNA interference has also generated much interest as an 
alternate method for gene therapy, focusing on loss-of-
function  rather  than  gain-of-function.  Current  targets 
being  tested  include  cancer,  single  gene  disorders  and 
viral  infections  (reviewed  in  Caplen,  2004).  The  FP-
shRNA system is perfectly suited as a vector for these 
applications.  In  addition  to  the  benefits  stated  above 
over  plasmid-  and  viral-based  systems,  the  FP 
transposon is expected to be active in many, if not all, 
human cell types. 
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